Biofidelity Revolutionising genomic analysis
3 known investors
Find your way into Biofidelity Revolutionising genomic analysis
Biofidelity develops decentralized biomarker testing solutions, starting with Aspyre Lung Reagents for analyzing DNA and RNA variants in lung cancer research. The company enables genomic testing on existing qPCR platforms globally, avoiding the cost and complexity of next-generation sequencing.
Founders & leadership
BB
Barnaby Balmforth, PhD
JS
Jonathan Senior, MD
MS
Magdalena Stolarek-Januszkiewicz, PhD
SK
Simon Knight
SH
Sophie Hackinger, PhD
Investors · 3
Frequently asked questions
- What does Biofidelity Revolutionising genomic analysis do?
- Biofidelity develops decentralized biomarker testing solutions, starting with Aspyre Lung Reagents for analyzing DNA and RNA variants in lung cancer research. The company enables genomic testing on existing qPCR platforms globally, avoiding the cost and complexity of next-generation sequencing.
- Who founded Biofidelity Revolutionising genomic analysis?
- Biofidelity Revolutionising genomic analysis was founded by Barnaby Balmforth, PhD.
- Who are Biofidelity Revolutionising genomic analysis's investors?
- Biofidelity Revolutionising genomic analysis's investors include Longwall Venture Partners LLP, Octopus Ventures, Perscitus LLP.